Inclusion Criteria:
Adult participants, at least 18 years of age at time of treatment decision
- Diagnosis of advanced/metastatic renal cell carcinoma (RCC) (confirmed by histology or
cytology)
- Treatment decision to initiate a treatment with nivolumab and ipilimumab or nivolumab
for the first time for the treatment of advanced/metastatic RCC (according to the
label approved in Germany) has already been taken
- Signed informed consent
Exclusion Criteria:
- Participants with a diagnosis of a cancer other than advanced/metastatic advanced RCC
within the past five years, ie, a cancer other than advanced/metastatic RCC that
requires systemic or other treatment. Participants that have been treated curatively
more than five years ago with no evidence of recurrence and prostate cancer patients
in active surveillance can be included.
- Participants previously treated with nivolumab and/or ipilimumab
- Participants currently included in an interventional clinical trial for their locally
advanced or metastatic RCC. Participants who have completed their participation in an
interventional trial; or who are not receiving study drug anymore and who are only
followed-up for OS can be enrolled.
